US EditionArvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for ...
- Arvinas and Pfizer presented positive Phase 3 VERITAC-2 trial results on May 31, 2025, in Chicago for vepdegestrant versus fulvestrant in ER+/HER2- advanced breast cancer patients with ESR1 mutations.
- The trial tested vepdegestrant, an oral PROTAC ER degrader, in 624 patients previously treated with CDK4/6 inhibitors and endocrine therapy, focusing on those with ESR1 mutations that confer treatment resistance.
- Vepdegestrant improved median progression-free survival to 5.0 months from 2.1 months with fulvestrant among 270 ESR1-mutant patients, showing a hazard ratio of 0.57 and a P value under 0.001.
- While generally well tolerated with fewer gastrointestinal events, grade 3 adverse events occurred in 23.4% of vepdegestrant patients versus 17.6% with fulvestrant, and discontinuations were low at 2.9%.
- These results support a planned FDA New Drug Application submission in late 2025, though further follow-up is needed and regulatory and clinical risks remain for the drug's future use and commercial success.
17 Articles
17 Articles
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly longer progression-free survival in patients with ESR1 mutations, according to a study published online May 31 in the New England Journal of Medicine. The research was presented to coincide with the annual meeting of the Americ…
Breakthrough in Breast Cancer Treatment: Pfizer and Arvinas' Promising Results
Breakthrough in Breast Cancer Treatment: Pfizer and Arvinas' Promising Results Pfizer and Arvinas have announced promising results from their experimental breast cancer treatment. The drug, vepdegestrant, has demonstrated an ability to delay cancer progression significantly longer than AstraZeneca's Faslodex in patients with specific gene mutations.The trial results, revealed at the American Society of Clinical Oncology meeting in Chicago and pu…
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression
(Reuters) -An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca’s Faslodex in patients with a specific gene mutation, according to trial results announced on Saturday. The findings were presented in Chicago at the annual meeting of the American Society of Clinical Oncology and published in The New England Journal of Medicine. The trial found the experimental drug v…
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for ...
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low…
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a …
Coverage Details
Bias Distribution
- 88% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
